Edwards Lifesciences Corporation (NYSE:EW) is considered one of the best healthcare stocks to buy for 2026. Stifel recently raised its price target for EW to $110 from $105, signaling a positive outlook for the company’s growth potential.

The price target increase comes as a response to a rise in Transcatheter Aortic Valve Replacement (TAVR) procedures, indicating a significant growth trend in the market. This aligns with Edwards Lifesciences’ strong revenue growth, particularly in the TAVR division, which accounts for 75% of total revenue.

TD Cowen also upgraded Edwards Lifesciences to a Buy rating and raised the price target to $97 from $90. The company’s renewed growth cycle, driven by expanded indications for TAVR, has attracted positive attention from analysts and investors.

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company specializing in heart disease innovations and critical care monitoring. With a focus on patient-centered solutions, the company has positioned itself as a leader in the healthcare industry.

While Edwards Lifesciences shows promise as an investment, some analysts believe that certain AI stocks may offer greater potential and lower risk. Investors looking for undervalued AI stocks should consider exploring other options for maximizing returns.

Read more at Yahoo Finance: Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW)